Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
160.25 x 100 161.98 x 100
Post-market by (Cboe BZX)
161.72 +0.70 (+0.43%) 03/26/25 [NYSE]
160.25 x 100 161.98 x 100
Post-market 161.75 +0.03 (+0.02%) 16:45 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
160.64
Day High
162.49
Open 161.21
Previous Close 161.02 161.02
Volume 7,223,700 7,223,700
Avg Vol 9,110,530 9,110,530
Stochastic %K 14.11% 14.11%
Weighted Alpha +4.65 +4.65
5-Day Change -1.27 (-0.78%) -1.27 (-0.78%)
52-Week Range 140.68 - 169.99 140.68 - 169.99
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 388,033,728
  • Shares Outstanding, K 2,409,848
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 14,023 M
  • EBITDA $ 21,362 M
  • 60-Month Beta 0.47
  • Price/Sales 4.43
  • Price/Cash Flow 12.44
  • Price/Book 5.50

Options Overview Details

View History
  • Implied Volatility 16.96% ( -0.30%)
  • Historical Volatility 15.62%
  • IV Percentile 53%
  • IV Rank 40.02%
  • IV High 23.61% on 01/10/25
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.73
  • Today's Volume 23,003
  • Volume Avg (30-Day) 36,389
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 405,918
  • Open Int (30-Day) 452,172

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.59
  • Number of Estimates 7
  • High Estimate 2.66
  • Low Estimate 2.51
  • Prior Year 2.71
  • Growth Rate Est. (year over year) -4.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
160.55 +0.73%
on 03/25/25
Period Open: 163.08
169.99 -4.86%
on 03/04/25
-1.36 (-0.83%)
since 02/26/25
3-Month
140.68 +14.96%
on 01/10/25
Period Open: 145.58
169.99 -4.86%
on 03/04/25
+16.14 (+11.09%)
since 12/26/24
52-Week
140.68 +14.96%
on 01/10/25
Period Open: 155.77
169.99 -4.86%
on 03/04/25
+5.95 (+3.82%)
since 03/26/24

Most Recent Stories

More News
Take the Zacks Approach to Beat the Markets: CMS Energy, Chevron, AutoZone in Focus

Last week, the Nasdaq Composite and the S&P 500 declined 0.14% and 0.13%, respectively. The Dow Jones Industrial Average gained 0.34% in the same period. Investor sentiment is still hung upon President...

PPC : 52.59 (+2.98%)
PRMB : 34.06 (+1.61%)
CVX : 167.97 (+1.22%)
KO : 70.02 (+1.76%)
AZO : 3,681.68 (+0.26%)
JNJ : 161.72 (+0.43%)
TKOMY : 39.9105 (-0.37%)
CMS : 73.31 (+1.76%)
ICE : 175.76 (+0.07%)
SGIOY : 7.6700 (-1.16%)
UBER : 74.18 (-1.89%)
NOBL : 101.38 (+0.85%)
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan

Last week, J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States as the Trump administration considers imposing tariffs...

ITCI : 131.69 (-0.01%)
JNJ : 161.72 (+0.43%)
KVUE : 23.40 (+1.30%)
AMGN : 305.71 (-0.37%)
J&J to Invest $55B in United States to Boost Manufacturing, R&D

J&J JNJ announced plans to invest more than $55 billion in the United States over the next four years to boost manufacturing, R&D and technology in the country.  This represents a 25% increase in investment compared...

JNJ : 161.72 (+0.43%)
LLY : 826.76 (-3.00%)
PFE : 25.21 (-1.33%)
3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

NVDA : 113.76 (-5.74%)
KO : 70.02 (+1.76%)
$SPX : 5,712.20 (-1.12%)
PG : 166.58 (+2.29%)
JNJ : 161.72 (+0.43%)
Kenvue Stock In Focus As TOMS Capital Reportedly Pushes For Sale Or Breakup: Will It Shift Retail Mood?

Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of back-and-forth....

JNJ : 161.72 (+0.43%)
KVUE : 23.40 (+1.30%)
IPO : 39.26 (-3.18%)
FPX : 117.97 (-2.68%)
Stock market today: Wall Street closes higher, snapping a 4-week losing streak

U.S. stocks shook off a weak start and ended slightly higher, enough to break a four-week losing streak

NVDA : 113.76 (-5.74%)
AAPL : 221.53 (-0.99%)
$SPX : 5,712.20 (-1.12%)
JNJ : 161.72 (+0.43%)
MU : 92.13 (-2.18%)
NKE : 65.74 (-1.20%)
$IUXX : 19,916.99 (-1.83%)
DAL : 48.07 (-1.23%)
MSFT : 389.97 (-1.31%)
LMT : 445.17 (+0.70%)
DRI : 207.45 (+0.14%)
$DOWI : 42,454.79 (-0.31%)
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3...

AZN : 72.72 (-0.45%)
JNJ : 161.72 (+0.43%)
NVS : 110.14 (-0.22%)
PFE : 25.21 (-1.33%)
SNY : 54.50 (-1.71%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 161.72 (+0.43%)
MRK : 88.11 (+0.27%)
LLY : 826.76 (-3.00%)
ABBV : 201.30 (-0.02%)
Johnson & Johnson plans $55 billion in US investments over the next four years

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four new manufacturing plants

AAPL : 221.53 (-0.99%)
$SPX : 5,712.20 (-1.12%)
JNJ : 161.72 (+0.43%)
$DOWI : 42,454.79 (-0.31%)
$IUXX : 19,916.99 (-1.83%)
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon, or approximately...

JNJ : 161.72 (+0.43%)
HLN : 10.05 (+0.10%)
GSK : 38.31 (-0.70%)
PFE : 25.21 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 164.44
2nd Resistance Point 163.47
1st Resistance Point 162.59
Last Price 161.72
1st Support Level 160.74
2nd Support Level 159.77
3rd Support Level 158.89

See More

52-Week High 169.99
Last Price 161.72
Fibonacci 61.8% 158.79
Fibonacci 50% 155.33
Fibonacci 38.2% 151.88
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies